NX Prenatal

11 articles about NX Prenatal

• Thermo Fisher Scientific Announces Collaboration to Advance Noninvasive Risk Assessments of Pregnancy Outcomes

  4/16/2019

  Thermo Fisher and NX Prenatal to develop clinical mass spectrometry-based workflows for monitoring maternal and fetal health during pregnancy and evaluating risk of complications

• NX Prenatal Enters Collaboration to Develop High Throughput Clinical Mass Spec Proteomic Assays for NeXosome® Platform

  4/5/2019

  NX Prenatal Inc. announced that it has entered into a strategic collaboration with Thermo Fisher Scientific.

• NX Prenatal Announces Publication of Peer-Reviewed Study in the American Journal of Obstetrics & Gynecology for Validation of First Trimester Preterm Birth Risk Biomarkers

  2/28/2019

  The findings represent the first reported multi-site validation of blood-based biomarker panels at 10-12 weeks gestation to stratify pregnant patients for the risk of preterm birth

• NX Prenatal and Milu Labs Announce Strategic Collaboration to Commercialize Exosome-Based Preterm Birth Risk Test in Asia

  1/16/2019

  NX Prenatal Inc., a privately held women's healthcare molecular diagnostic company, announced today that it has entered into a strategic collaboration with Milu Labs, whose mission is to become the leading diagnostics company in Asia with a focus on maternal fetal medicine and women's health.

• Expanding Applications of NX Prenatal's Exosome-Based Diagnostics Platform Presented at Key Conferences

  11/13/2018

   NX Prenatal Inc. announced today that expanding applications of its proprietary NeXosome® liquid biopsy platform were presented at recent scientific conferences.

• NX Prenatal Announces Key Clinical Validation Trial of its Exosome-Based Blood Test for Preterm Birth Risk in Collaboration with Indiana University School of Medicine

  10/24/2018

  NX Prenatal, a privately held women's healthcare molecular diagnostic company, announced today that it has entered into a collaboration with Indiana University School of Medicine to further validate its early pregnancy biomarker panels that predict Spontaneous Preterm Birth (SPTB) and to further develop its biomarker panels for Preeclampsia (PE).

• NX Prenatal Release: Company Appoints Leading Experts To Medical/Clinical Advisory Board

  1/20/2017

• NX Prenatal Names Dr. Kevin Rosenblatt Chief Medical And Scientific Officer

  10/24/2016

• NX Prenatal Announces Strategic Partnership With NxGEN MDx To Develop And Commercialize Preterm Birth Risk Stratification Test

  7/28/2016

• NX Prenatal Premature Birth Biomarker Study Published In Prestigious American Journal Of Obstetrics And Gynecology

  3/23/2016

• New NX Prenatal Preterm Birth Risk Biomarker Data Presented At Society For Maternal Fetal Medicine Annual Meeting

  2/10/2016